
    
      An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of
      oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with
      relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    
  